Horizon 2020: The European Union research and innovation programme 2014-2020 SEVENTH EDCTP FORUM: THE PARTNERSHIP JOURNEY - NEW HORIZON FOR BETTER HEALTH Berlin Line Matthiessen European Commission Research and Directorate General Health Directorate Head of Unit:'Fighting infectious diseases and global epidemics Line.matthiessen@ec.europa.eu
Overview Ø Our routes to Horizon 2020 Ø Horizon 2020: general features and state of play Ø Health, Demographic Change and Wellbeing societal challenge
Why the EU supports (Article 179 190, Treaty on the Functioning of the EU) Investing in future growth and development Strengthening the EU s global position in research, innovation and technology (European Research Area) Addressing people s concerns about their livelihoods, safety and environment in Europe and beyond Supporting competitiveness & improving quality of life
30 years of EU funded R&I Annual budget (in b )
European Commission - A key player in global health research World's 3 rd largest funder of research on poverty-related and neglected infectious diseases (after NIH and BMGF) 1,2 billion invested in global health research since 2007
A stairway to global health research collaboration Since 1984 The EU Framework Programme for Research and (FP) 9 Collaboration between scientists from academia and industry 9 Health, Demographic Change and Well-being 9 European Research Council (2007) 9 Marie-Curie-Actions Since 2003 Strategic cooperation with public and private European funders 9 with European countries: EDCTP (2003) 9 with European industry (EFPIA): IMI (2004/07) 9 joint programmes, such as on antimicrobial resistance (2010) Now Strategic cooperation with other public/private funders worldwide/across sectors 9 Global Alliance on Chronic Diseases (GACD, 2009) 9 Global Research Collaboration for Infectious Disease Preparedness (GloPID-R, 2013) 9 Global TB Vaccine Partnership (GTBVP, 2014/15) 9 MOU with BMGF; Gulbenkian foundation European Commission's Inducement Prizes e.g. 1 st prize awarded in March 2014 for innovation on thermo stable vaccines for Global Health
International cooperation in the Health programme under FP7 (2007-2013) 84 countries 827 participations 210 million
EC contribution by regions/areas
Overview Ø Our routes to Horizon 2020 Ø Horizon 2020: general features and state of play Ø Health, Demographic Change and Wellbeing societal challenge
What is Horizon 2020? The new EU programme for research and innovation 79 billion over 7 years (2014-2020) An integrated programme coupling research to innovation Challenge based Strong focus on SMEs Major simplification Open to the world
What Horizon 2020 is not: Ø It is not a development aid programme Ø It is not a bilateral cooperation programme It is a research programme focussed on European needs and global challenges, open to international cooperation.
Three priorities Excellent science Industrial leadership Societal challenges
79 billion from 2014 to 2020
European Research Council Future and Emerging Technologies Marie Skłodowska-Curie actions Research infrastructures Leadership in enabling and industrial technologies Access to risk finance in SMEs Horizon 2020 and its three pillars Industrial leadership Excellent science Societal challenges Health, demographic change and wellbeing Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the Bioeconomy Secure, clean and efficient energy Smart, green and integrated transport Climate action, environment, resource efficiency and raw materials Inclusive, innovative and reflective societies Secure societies
Other programmes where health research may be funded Ø Frontier research (European Research Council) Ø Marie Skłodowska-Curie actions Ø Leadership in enabling and industrial technologies Ø Search by key-word @ https://ec.europa.eu/research/participants/portal/ desktop/en/opportunities/h2020/search/ search_topics.html
Overview Ø Our routes to Horizon 2020 Ø Horizon 2020: general features and state of play Ø Health, Demographic Change and Wellbeing societal challenge
Health research in Societal Challenge 1 (SC1) Health, Demographic Change and Wellbeing 7. 47 billion Collaborative research Global initiatives GACD, GloPID-R, IRDiRC.. Public-private partnerships Public-public partnerships Central globe image rtguest/fotolia.com Global cooperation image courtesy freedigitalfotos.com/ phanlop88 Collaborative RESEARCH image courtesy freedigitalfotos.com/ photostock
International cooperation A priority through all Horizon 2020 Ø Key goal: access knowledge, Europe as an attractive location, join forces to tackle global challenges Ø Objective: 10% of participants in funded projects by 2020 Ø Horizon 2020 is open to participation from across the world but Ø funding to Third countries is not automatic! è N.B. Third country = any country not being a Member State, MS, or Associated Country, AC
Automatic funding: General opening Ø MS, AC, International European interest organisations Ø Exhaustive list of countries available @ http:// ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/ annexes/h2020-wp1415-annex-a-countries-rules_en.pdf No automatic funding: Ø Australia, Brazil, Canada, China, Japan, India, South Korea, Mexico, New Zealand, Russia, etc. Ø International organisations established in Third countries Ø Exceptions (article 10 of the Rules for participation and dissemination under Horizon 2020)
Health research in Societal Challenge 1 (SC1) Health, Demographic Change and Wellbeing 7. 47 billion Collaborative research Global initiatives GACD, GloPID-R, IRDiRC.. Public-private partnerships Public-public partnerships Central globe image rtguest/fotolia.com Global cooperation image courtesy freedigitalfotos.com/ phanlop88 Collaborative RESEARCH image courtesy freedigitalfotos.com/ photostock
Multi-lateral health research activities: an experience that will continue International K.O. Mouse Consortium Global Alliance for Chronic Diseases International Human Epigenome Consortium International Rare Disease Research Consortium International Cancer Genomics Consortium International Initiative for Traumatic Brain Injury Research International Human Microbiome Consortium New! Global Research Collaboration for Infectious Disease Preparedness
Health research in Societal Challenge 1 (SC1) Health, Demographic Change and Wellbeing 7. 47 billion Collaborative research Global initiatives GACD, GloPID-R, IRDiRC.. Public-private partnerships Public-public partnerships Central globe image rtguest/fotolia.com Global cooperation image courtesy freedigitalfotos.com/ phanlop88 Collaborative RESEARCH image courtesy freedigitalfotos.com/ photostock
Innova&ve Medicines Ini&a&ve 2007-2013
IMI2: main novelties IMI2, originated from IMI, is the biggest public/private partnership in Life Science Ø Mission: to create a powerful research and innovation "machine", with broader objectives, activities and partners Ø Budget: around 3.28 billion euro, equally shared between public and private partners
IMI2 Scope and Objectives IMI2 will expand the scope of IMI1 to cover the entire medical research and innovation value chain: Ø Actively involve life science industries other than pharmaceuticals; for example the vaccine, the animal health or the biomedical imaging industry Enable top quality research and innovations with great public health benefits and commercial possibilities Pave the way for the breakthrough vaccines, medicines and treatments which we will need in the near future: Ø Develop new therapies for diseases with high unmet need, such as Alzheimer's disease, and limited market incentives, such as antimicrobial resistance
Health research in Societal Challenge 1 (SC1) Health, Demographic Change and Wellbeing 7. 47 billion Collaborative research Global initiatives GACD, GloPID-R, IRDiRC.. Public-private partnerships Public-public partnerships Central globe image rtguest/fotolia.com Global cooperation image courtesy freedigitalfotos.com/ phanlop88 Collaborative RESEARCH image courtesy freedigitalfotos.com/ photostock
The Work Programme (2014) 2015 Call 'personalising health and care' 34 topics (15 in 2014, 17 in 2015, 2 open in both years) 1,21 billion Call for 'co-ordination activities' 16 topics (10 in 2014, 6 in 2015)
Health, Demographic change and wellbeing An integrated approach with 7 focus areas for 2014-2015 Ø Understanding health, ageing & disease Ø Effective health promotion, disease prevention, preparedness and screening Ø Improving diagnosis Ø Innovative treatments and technologies Ø Advancing active and healthy ageing Ø Integrated, sustainable, citizen-centred care Ø Improving health information, data exploitation and providing an evidence base for health policies and regulation + co-ordination activities and Strategic initiatives:
How does it work? EC publish workprogrammes covering 2 years Calls are published each year Workprogramme includes the call topics research priorities Most topics under H2020 are broard topics asking to provide solution for a broard challenge
Understanding the call topics: example 'PHC 2 2015' 'Specific challenge' 'Scope' 'Expected impact' 'Type of action'
SC1 Work Programme 2014-2015 some examples 1/2 PHC 9-2015) Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS Specific challenge: To shift the risk curve in order to better select successful vaccine candidates at an earlier stage of the process Scope Focus on strengthening the capacity for discovery and early development of new vaccine candidates for HIV/AIDS by: i) establishment of platform for novel candidates discovery, selection, pre-clinical and early clinical testing ii) tackling major bottleneck in vaccine development iii) the vaccine development shall continue in the context of EDCTP-2 To also address barriers and facilitators regarding the update and implementation of a new vaccine Expected Impact: To increase the chance of discovery of an effective therapeutic or preventive vaccine with reduced costs To establish close links to the European and Developing Countries Clinical Trials Partnership (EDCTP-2) Type of action: Research and innovation project
SC1 Work Programme 2014-2015 some examples 2/2 Understanding health, ageing & disease Systems medicine approaches (2015) (PHC 2) Common mechanisms of diseases and potential co-morbidities (2015) (PHC 3) Effective health promotion, disease prevention, preparedness and screening Inter-sector cooperation for environment- and health-based interventions (2015) (PHC4) Improving diagnosis In vivo medical imaging technologies (2015) (PHC 11) Innovative treatments and technologies Tools and technologies for advanced therapies (2015) (PHC 16) Comparing and establishing effectiveness of health interventions in the paediatric population (2015) (PHC 18)
From CALL to GRANT Publica&on of the calls Time to prepare the proposal Submission of proposals Evalua&on Signature grant agreement Finalisation of the grant Informa&on on the outcome of the evaluator
Overview of the Evaluation Process Involving evaluators Submission Individual reading Consensus meeting Panel meeting Finalisation Full Proposal Proposal forms Criteria Individual reports Criteria Consensus reports Criteria Proposals in suggested priority order Final ranking list Rejection list Eligibility COMMISSION remote on site COMMISSION
Evaluation of proposals STANDARD AWARD CRITERIA EXCELLENCE IMPACT QUALITY & EFFICIENCY OF THE ACTION
Time to grant: speeding up the process A maximum TTG of 8 months 5 months for informing all applicants on scientific evaluation 3 months for signature of Grant Agreement Some exceptions apply
More info @ Health Challenge: http://ec.europa.eu/programmes/ horizon2020/en/h2020-section/healthdemographic-change-and-wellbeing Info Day (information for proposers): http://ec.europa.eu/research/health/ horizon-2020-health-open-info-days_en.html Examples of projects funded in previous programmes: http://ec.europa.eu/research/health/ index_en.html